Tempus AI (NASDAQ:TEM) Stock Price Up 1.2% – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEMGet Free Report) rose 1.2% on Tuesday . The stock traded as high as $65.34 and last traded at $62.29. Approximately 8,355,728 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 10,424,641 shares. The stock had previously closed at $61.54.

Analysts Set New Price Targets

TEM has been the subject of several analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Loop Capital cut their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Check Out Our Latest Report on Tempus AI

Tempus AI Price Performance

The business has a 50 day simple moving average of $44.14 and a 200-day simple moving average of $48.44. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Transactions at Tempus AI

In related news, Director David R. Epstein sold 620 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total value of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,037,702 shares of company stock valued at $89,449,651 in the last three months.

Institutional Trading of Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the company. IFP Advisors Inc acquired a new position in Tempus AI during the fourth quarter worth $76,000. First Horizon Advisors Inc. increased its stake in Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after acquiring an additional 1,108 shares during the period. Sigma Planning Corp boosted its holdings in Tempus AI by 43.9% during the fourth quarter. Sigma Planning Corp now owns 33,638 shares of the company’s stock valued at $1,136,000 after purchasing an additional 10,269 shares in the last quarter. Private Advisor Group LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $1,344,000. Finally, Apollon Wealth Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $256,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Recommended Stories

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.